The TMPRSS2:ERG fusion and response to androgen deprivation therapy for prostate cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Androgen-regulated gene fusions, such as TMPRSS2:ERG, are common in prostate cancer.
• TMPRSS2:ERG fusion is present in approximately half of U.S. men with prostate cancer.
• The hypothesis posits that TMPRSS2:ERG positive tumors may enhance responsiveness to androgen deprivation therapy (ADT).

Purpose of the Study:

• To investigate the association between TMPRSS2:ERG fusion status and prostate cancer-specific mortality following ADT.
• To determine if the presence of the TMPRSS2:ERG fusion influences patient outcomes after ADT.

Main Methods:

• A cohort of 239 prostate cancer patients from the Physicians' Health Study and Health Professionals Follow-up Study who underwent ADT was analyzed.
• Tumor tissue was assessed for ERG protein expression via immunohistochemistry to determine fusion status.
• Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for prostate cancer mortality.

Main Results:

• The study included men with advanced-stage (T3+) and high-grade (Gleason 8-10) prostate cancer.
• Over a median follow-up of 10.2 years, 42 deaths from prostate cancer occurred.
• While the overall association between TMPRSS2:ERG fusion and mortality post-ADT was not significant (HR: 0.76), a significant reduction in mortality was observed in men treated with orchiectomy (HR: 0.13).

Conclusions:

• Findings suggest that men with TMPRSS2:ERG positive prostate cancer may experience improved survival after ADT.
• The data indicate a potential survival advantage, particularly for those treated with orchiectomy.
• Larger studies are warranted to confirm these findings and explore benefits in different treatment settings (e.g., neoadjuvant, adjuvant, metastatic).